Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROCODONE BITARTRATE

All products: not a benefit

Other products in the same Health Canada class (R05DA) — coverage varies; not interchangeable

  • Dextromethorphan hbr (DM-Syrup): general benefit, Not a benefit

Hycodan · DIN 01916580 · 1mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-07-14 — choose a marketed DIN from the same-category list.Discontinued 2017-07-14 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-07-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-07-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hycodan · DIN 01916580 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2017-07-14 · brand HYCODAN SYRUP · ATC R05DA03 HYDROCODONE · form Syrup · route Oral · ingredients HYDROCODONE BITARTRATE 5 MG/5ML · company Eirgen pharma limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Hycodan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13315 · Verify on the e-Formulary ↗ (DIN 01916580)

Source record
DIN 01916580: Hycodan Raw flags: notABenefit=Y, sec3=Y Item: 480400007; group id 572; item number 1524; lccId None; manufacturer id BQU Source form: O/L; strength: 1mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916580 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13315
Interchangeable products
PMS-Hydrocodone · DIN 02324253 · $0.0617
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2017-07-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (48:04 Antitussives) and how they are covered

Matched class: 48:04 Antitussives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): DEXTROMETHORPHAN HBR 48:04 Antitussives

DEXTROMETHORPHAN HBR

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 3mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 48:04
Full class listing Related classes: 48:08 Expectorants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults pdp-HYDROCODONE (hydrocodone bitartrate) is indicated for the control of exhausting, non- productive cough. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy. Pediatrics (< 18 years of age) pdp-HYDROCODONE is not indicated for use in patients younger than 18 years of age because of the risk of opioid toxicity due to the variable and unpredictable metabolism of hydrocodone to hydromorphone and because the benefits of symptomatic treatment of cough do not outweigh the risks for use of hydrocodone in these patients (see also CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics; and DOSAGE AND ADMINISTRATION). https://pdf.hres.ca/dpd_pm/00054223.PDF PM date: not printed or not captured Source product: PDP-HYDROCODONE; DIN 02324253; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Hycodan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026